Production of recombinant DNA-binding protein HMGB1 for diagnostic application
Public support
Provider
Ministry of Industry and Trade
Programme
TIP
Call for proposals
TIP 4 (SMPO2012/01)
Main participants
GENERI BIOTECH s.r.o.
Contest type
VS - Public tender
Contract ID
FR-TI4/504
Alternative language
Project name in Czech
Produkce rekombinantního DNA-vazebného proteinu HMGB1 pro diagnostické využití
Annotation in Czech
Tento projekt je zaměřen na vývoj imunoanalytické soupravy pro kvantifikaci HMGB1 ve vzorcích biologického původu s využitím ve výzkumu a vývoji a v diagnostice. Hlavní náplní je vývoj technologie přípravy vstupních komponent, tedy rekombinantního HMGB1a monoklonálních protilátek. Rekombinantní HMGB1 bude produkován s využitím různých produkčních systémů, tak aby bylo dosaženo biologické aktivity srovnatelné s nativním proteinem. Vedle využití HMGB1 v imunizacích a jako proteinového standardu v diagnostice, bude testován jeho potenciální terapeutický význam.
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
EB - Genetics and molecular biology
CEP - another secondary branch
—
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30101 - Human genetics<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
The aim of the project was technology for production of HMGB1 protein, antibodies against this protein and connection of the results into ELISA kit. Despite some difficulties targets were fulfilled. The final product, imunoanalytical kit.
Solution timeline
Realization period - beginning
Jan 1, 2012
Realization period - end
Dec 31, 2015
Project status
U - Finished project
Latest support payment
Apr 25, 2014
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP16-MPO-FR-U/03:1
Data delivery date
Feb 13, 2018
Finance
Total approved costs
17,650 thou. CZK
Public financial support
13,824 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
3,825 thou. CZK